Category - Developments

Closely held Braeburn Pharmaceuticals filed with U.S. regulators to raise up to $150-million in an initial public offering, seven months after its Probuphine implant to treat opioid addiction was approved by the FDA...

IntelGenx (OTCQX:IGXT; TSX-V:IGX) entered into a co-development and commercialization agreement with Endo Ventures for a new product utilizing IntelGenx’ proprietary VersaFilm for the USA market. Under the accord...

Dipexium Pharmaceuticals (NASDAQ:DPRX) and closely held PLx Pharma have agreed to merge in an all-stock transaction.  Following closing, Dipexium will be renamed PLx Pharma and will operate under the leadership of...

Sales for Microbix Biosystems (TSX:MBX) in the fourth quarter of fiscal 2016 climbed 64% to $3.5-million, representing the highest quarterly revenue ever achieved by the company, from $2.1-million a year earlier. Net...

The Motley Fool investment newsletter selected Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant as one of the 12 greatest medical breakthroughs of 2016. In May, the FDA approved the one-of-a-kind buprenorphine...

Arbutus Biopharma (NASDAQ:ABUS) and Spring Bank Pharmaceuticals (NASDAQ:SBPH) agreed to perform collaborative preclinical studies in chronic Hepatitis B virus (HBV). The accord involves the co-administration of Spring...

3D Signatures (TSX-V:DXD) issued 5,187,618 units under a brokered private placement at a price of 75 cents a unit for gross proceeds of about $3.9-million, including a partial exercise of an over-allotment option. Each...

Adamis Pharmaceuticals (NASDAQ:ADMP) has resubmitted its NDA to the FDA for its Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis. The resubmission is intended to address...

IntelGenx (OTCQX:IGXT; TSX-V:IGX) and RedHill Biopharma (NASDAQ,:RDHL; TASE:RDHL) have signed an exclusive license agreement with Pharmatronic for the commercialization of Rizaport in South Korea. Rizaport is a...

Arbutus Biopharma (NASDAQ:ABUS) reported new results from the ongoing Phase 2 study of ARB-1467 in chronically infected HBV patients on stable nucleoside therapy, and plans to add a fourth cohort of patients to the...